Biotech and Pharmaceuticals Pharmaceuticals


  • Bayer offers $122 per share for Monsanto

    The pharmaceutical company Bayer has announced plans to acquire American biotech company Monsanto, making an all cash offer of $122 per share.

  • SHANGHAI, May 23- Promises of higher salaries and greater freedom at work are luring officials from China's high-profile drugs watchdog to the companies they had regulated, a blow just as the country looks to tighten oversight and drive innovation. China wants to crack down on substandard drugs and healthcare as it seeks to produce more of the drugs consumed in...

  • Sarepta awaits drug approval

    CNBC's Meg Tirrell talks about whether the FDA will approve Sarepta's Muscular Dystrophy drug and what could happen to the company's stock. The "FMHR" traders debate the trade.

  • SHANGHAI/ LONDON, May 20- Chinese health authorities announced price cuts of up to two-thirds for three drugs on Friday in the latest move to reduce the cost of healthcare for patients in the world's second-biggest economy. Icotinib, another lung cancer drug made by China's Betta Pharmaceuticals, will come down to 5,500 from 12,000 yuan a month.

  • May 19- Beleaguered Canadian drugmaker Valeant Pharmaceuticals International Inc said it received a notice of default from bondholders for the delay in filing its first-quarter report. Last week, Valeant had said it expected to file the report with U.S. and Canadian regulators on or before June 10, ahead of a July 31 deadline. The Laval, Quebec- based company's...

  • May 19- Beleagured Canadian drugmaker Valeant Pharmaceuticals International Inc said it received a notice of default from bondholders for the delay in filing its quarterly report. The Laval, Quebec- based company said it can avert default by filing the report by July 18. Last week, the company said it expected to file its first-quarter report with U.S. and...

  • Elizabeth Holmes, founder and CEO of Theranos.

    Blood-testing startup Theranos posted a job opening Thursday looking for an executive assistant to CEO Elizabeth Holmes.

  • NEW YORK, May 19- Late in July 2012, Phil Mickelson, one of the world's most famous golfers, received a phone call from a well-known professional sports gambler, William "Billy" Walters. "Simply put, Mickelson made money that wasn't his to make," Andrew Ceresney, the SEC's enforcement chief, said at a news conference in New York on Thursday. Mickelson, 45, was named as a "...

  • *CEO stands by peak annual sales forecast of $5 billion. ZURICH, May 19- Novartis's heart failure drug Entresto will be subjected to a battery of new trials as the Swiss drugmaker seeks to boost the medicine after a disappointing introduction. Entresto's stuttering launch was overseen by Novartis pharma chief David Epstein, who quit this week.

  • Illustration of the Zika virus.

    IBM's World Community Grid links volunteers' personal computers and mobile devices to form a supercomputer for disease research.

  • German drug and chemicals giant Bayer has made an unsolicited takeover offer for Monsanto, the world's biggest seed company.

  • Need to exit comfort zone to solve antibiotic problem: O’Neill

    Lord (Jim) O'Neill, chairman of the Review on Antimicrobial Resistance, explains why pharmaceutical firms are crucial to the supply of new drugs, and how they should be rewarded for their discoveries.

  • A rare and previously unknown variation in some people's genes substantially reduces their heart attack risk, the Icelandic researchers said.

  • J&J CEO: Disappointed in talcum verdict findings

    CNBC's Meg Tirrell reports on Johnson & Johnson after it lost a second lawsuit linking its baby powder to cancer, and speaks with CEO Alex Gorsky at the company's analyst day.

  • Tecentriq won accelerated approval Wednesday from the Food and Drug Administration for treating patients with advanced urothelial cancer after chemotherapy stops helping them— a point when most usually die within about six months. Testing on many more patients to confirm the early results, which is required to obtain full approval from the FDA, is in...

  • May 18- The U.S. Food and Drug Administration on Wednesday granted accelerated approval for Roche Holding AG's immunotherapy for the most common form of bladder cancer, marking the company's entry into a lucrative class of drugs. The drug, Tecentriq, targets the PD-1/PD-L1 pathway, which helps the immune system fight cancer by blocking a mechanism tumors use to...

  • Alex Gorsky chairman and CEO Johnson & Johnson.

    J&J's consumer brands and medical devices units are poised for growth following turnaround efforts, CEO Alex Gorsky says.

  • *Dr Reddy's, Glenmark have invested heavily in Venezuela. MUMBAI/ NEW DELHI, May 18- Indian officials say they have proposed an oil-for-drugs barter plan with cash-strapped Venezuela to recoup millions of dollars in payments owed to some of India's largest pharmaceutical companies. Several of India's generics producers, led by the country's second-largest...

  • Disrupting diabetes: CEO

    Kurt Graves, Intarcia Therapeutics CEO, discusses how the company's product eliminates the need for daily injections for type 2 diabetes and instead delivers a steady dose of medicine over the course of a year,

  • May 18- Tiny Israeli drugmaker Oramed Pharmaceuticals Inc on Wednesday said its experimental oral insulin succeeded in significantly reducing night-time blood glucose in patients with type 2 diabetes, according to initial data from a midstage trial. The result is likely to surprise many skeptics who did not believe insulin could be delivered orally...